ARCHIVES

Over Half of ALK-Positive NSCLC Patients Responded To Crizotinib In Colorado Study

This article is from The Cancer Letter archive.

Vol. 33 No. 11 | November 26, 2010

Download PDF Visit The Full Archive

Related Articles

Mammography: Panel Member Quits Over “One-Sided” Document

February 14, 1997

Karmanos Cancer Institute, CDC, Blue Cross To Begin Environmental Cancer Program

June 4, 2010

Bush Asks Hammer To Probe FDA Regulation Of Anticancer Drugs

June 17, 1988

NCI, NSF fund awards in nanotech training.

September 23, 2005

Rep. Bliley Challenges FDA On Failure To Approve Oral Colon Cancer Drug UFT.

April 21, 2000

Clinical Trials Approved By NCI CTEP During July

August 30, 2002